
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

December 30, 2021
Date of Report (date of earliest event reported)

NovoCure Limited

(Exact name of registrant as specified in its charter)

| | | |
|--|---|---|
| Jersey (State or other jurisdiction of incorporation or organization) | 001-37565 (Commission File Number) | 98-1057807 (I.R.S. Employer Identification No.) |
| No. 4 The Forum, Grenville Street St. Helier Jersey (Address of Principal Executive Offices) | | JE2 4UF (Zip Code) |

+44 (0) 15 3475 6700
Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|-------------------------------|-------------------|---|
| Ordinary Shares, no par value | NVCR | The Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On December 30, 2021, NovoCure Limited (the "Company") through its indirect wholly-owned subsidiary, Novocure Inc., closed on its previously announced acquisition of an office building located at 64 Vaughan Mall in downtown Portsmouth, New Hampshire (the "Property") pursuant to a Purchase and Sale Agreement (the "Purchase Agreement") with 64 Vaughan Mall, LLC (the "Seller") dated December 1, 2021, and entered into a construction agreement (the "Construction Agreement" and collectively with the Purchase Agreement, the "Agreements") with Hampshire Development Corporation, an affiliate of Seller.

The Agreements will be filed as exhibits to the Company's annual report on Form 10-K for the fiscal year ended December 31, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovoCure Limited
(Registrant)

Date: December 30, 2021

By: /s/ Ashley Cordova
Name: Ashley Cordova
Title: Chief Financial Officer